Bezlotoxumab, sold under the brand name Zinplava, is a human

monoclonal antibody A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodie ...

designed for the prevention of recurrence of ''Clostridioides difficile'' infections. Bezlotoxumab binds to ''Clostridioides difficile'' toxin B.

Medical uses

Bezlotoxumab is

indicated In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis ...

to reduce recurrence of ''Clostridioides difficile'' infection in people who are receiving antibacterial drug treatment for ''Clostridioides difficile'' infection and are at a high risk for ''Clostridioides difficile'' infection recurrence.

Mechanism of TcdB neutralization

By x-ray crystallized structure of N-terminal of ''Clostridioides difficile'' toxin B (TcdB), the toxin was identified to consist of three domains: a GTD, a

cysteine protease Cysteine proteases, also known as thiol proteases, are hydrolase enzymes that degrade proteins. These proteases share a common catalytic mechanism that involves a nucleophilic cysteine thiol in a catalytic triad or dyad. Discovered by Gopal Chu ...

and a combined repetitive oligopeptides, CROP domain. The CROP domain consists of four different peptide units: B1, B2, B3, and B4. Bezlotoxumab specifically inhibits the CROP domain of TcdB. It recognizes a specific epitope on toxin TcdB and has a high affinity for that region. The GTD domain does not interact with bezlotoxumab, but appears to interact with B1, which is representative of the entire CROP domain. Bezlotoxumab interacts with either B2 and B3 or the overlapping residues region between the two domains. The B4 fragment does not interact with the specific portion of the CROP domain. Characterization of peptide B1 as full CROP domain of TcdB suggests that the antibody specifically reacts with the B2 region of the CROP domain. This leads to the conclusion that the TcdB epitope lies within the N-terminus of the CROP domain.

History

This drug, along with actoxumab, was developed through phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the

University of Massachusetts Medical School The UMass Chan Medical School is a public medical school in Worcester, Massachusetts. It is part of the University of Massachusetts system. It consists of three schools: the T.H. Chan School of Medicine, the Morningside Graduate School of Biom ...

. The project was then licensed to Merck Sharp & Dohme Corp for further development and commercialization. A phase III trial only showed a benefit from bezlotoxumab; the combination of actoxumab and bezlotoxumab worked no better to prevent a recurrence of ''C. difficile'' associated diarrhea than bezlotoxumab alone. In June 2016, the Antimicrobial Drugs Advisory Committee of the US

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...

voted to recommend approval of Merck's license application for bezlotoxumab by a vote of 10 to 5, generally expressing a willingness to accept that the trials had proven that bezlotoxumab decreased recurrence of ''C. difficile'' overall. The committee tempered this acceptance with a robust discussion of whether or not the drug provides a more marked benefit in some patient groups and expressed concern over a potential safety signal in the group treated with bezlotoxumab. The data suggested that bezlotoxumab might have the most benefit in sicker, high-risk patients but did show a statistical benefit in all patient subgroups. Although the patient population as a whole contained many very sick individuals and thus there were many adverse events in both the subjects receiving a placebo and those receiving bezlotoxumab, the panel focused on a small number of serious events in patients with pre-existing congestive heart failure. In this subset, the patients receiving bezlotoxumab appeared to have a higher rate of negative outcomes than the placebo group, although there may have been an imbalance in how sick the patients in those groups were. Bezlotoxumab was approved for medical use in the United States in October 2016.

References

{{Authority control Monoclonal antibodies Antibiotics Drugs developed by Merck & Co.